Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Phase III study of AG-221(CC-90007) with late AML harboring Isocitrate Dehydrogenase 2 mutation
Clinical Trial Grant
Duke Scholars
Principal Investigator
Carlos Manuel de Castro III
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
Celgene Corporation
Start Date
May 1, 2016
End Date
July 3, 2019
Awarded By
Celgene Corporation
Start Date
May 1, 2016
End Date
July 3, 2019
